John M Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9078489/publications.pdf

Version: 2024-02-01

45 papers

2,366 citations

304743

22

h-index

233421 45 g-index

46 all docs

46 docs citations

46 times ranked

3695 citing authors

#	Article	IF	CITATIONS
1	Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. American Journal of Psychiatry, 2017, 174, 927-942.	7.2	338
2	Dose Response and Dose Equivalence of Antipsychotics. Journal of Clinical Psychopharmacology, 2004, 24, 192-208.	1.4	289
3	Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ, The, 2016, 353, i1246.	6.0	266
4	Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. British Journal of Psychiatry, 2016, 209, 192-201.	2.8	150
5	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. American Journal of Psychiatry, 2020, 177, 342-353.	7.2	137
6	Design and implementation of Metta, a metasearch engine for biomedical literature retrieval intended for systematic reviewers. Health Information Science and Systems, 2014, 2, 1.	5.2	109
7	Initial Severity of Schizophrenia and Efficacy of Antipsychotics. JAMA Psychiatry, 2015, 72, 14.	11.0	94
8	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet, The, 2022, 399, 824-836.	13.7	88
9	Interaction between oxytocin receptor DNA methylation and genotype is associated with risk of postpartum depression in women without depression in pregnancy. Frontiers in Genetics, 2015, 6, 243.	2.3	82
10	How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Medicine, 2015, 13, 253.	5.5	77
11	Diet-Induced Changes in n-3- and n-6-Derived Endocannabinoids and Reductions in Headache Pain and Psychological Distress. Journal of Pain, 2015, 16, 707-716.	1.4	58
12	A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch. Science Signaling, 2017, 10, .	3.6	58
13	Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache. Pain, 2015, 156, 587-596.	4.2	56
14	Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. BMC Medicine, 2015, 13, 82.	5.5	46
15	Dietary linoleic acid-induced alterations in pro- and anti-nociceptive lipid autacoids. Molecular Pain, 2016, 12, 174480691663638.	2.1	44
16	Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ, The, 2021, 374, n1448.	6.0	43
17	Plasma oxytocin explains individual differences in neural substrates of social perception. Frontiers in Human Neuroscience, 2015, 9, 132.	2.0	41
18	Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2017, 78, e758-e765.	2,2	41

#	Article	IF	Citations
19	Automated confidence ranked classification of randomized controlled trial articles: an aid to evidence-based medicine. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 707-717.	4.4	40
20	Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology, 2019, 236, 545-559.	3.1	33
21	Personality, Behavior and Environmental Features Associated with OXTR Genetic Variants in British Mothers. PLoS ONE, 2014, 9, e90465.	2.5	29
22	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. British Journal of Psychiatry, 2017, 211, 127-129.	2.8	29
23	Issues that May Determine the Outcome of Antipsychotic Trials: Industry Sponsorship and Extrapyramidal Side Effect. Neuropsychopharmacology, 2008, 33, 971-975.	5.4	25
24	Old versus new: weighing the evidence between the first- and second-generation antipsychotics. European Psychiatry, 2005, 20, 7-14.	0.2	21
25	Parental, Prenatal, and Neonatal Associations With Ball Skills at Age 8 Using an Exposome Approach. Journal of Child Neurology, 2014, 29, 1390-1398.	1.4	14
26	Neuroactive steroids and depression in early pregnancy. Psychoneuroendocrinology, 2021, 134, 105424.	2.7	14
27	Concordance of Immune-Related Markers in Lymphocytes and Prefrontal Cortex in Schizophrenia. Schizophrenia Bulletin Open, 2021, 2, sgab002.	1.7	14
28	Allopregnanolone in Postpartum Depression. Frontiers in Global Women S Health, 2022, 3, 823616.	2.3	14
29	Aggregator: A machine learning approach to identifying MEDLINE articles that derive from the same underlying clinical trial. Methods, 2015, 74, 65-70.	3.8	13
30	Should We Treat Depression with drugs or psychological interventions? A Reply to Ioannidis. Philosophy, Ethics, and Humanities in Medicine, 2011, 6, 8.	1.5	11
31	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. Schizophrenia Bulletin, 2020, 46, 496-504.	4.3	11
32	Prevention of lithium-associated renal failure: recent evidence. Lancet Psychiatry, the, 2015, 2, 1045-1047.	7.4	10
33	Antipsychotic drugs: from â€~major tranquilizers' to Neuroscience-based-Nomenclature. Psychological Medicine, 2021, 51, 522-524.	4.5	10
34	Commentary on strategies for switching antipsychotics. BMC Medicine, 2008, 6, 18.	5.5	8
35	Are Patients With Schizophrenia Better Off With Lifetime Antipsychotic Medication?. Journal of Clinical Psychopharmacology, 2020, 40, 145-148.	1.4	7
36	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. Schizophrenia Research, 2021, 229, 3-11.	2.0	7

#	Article	IF	CITATIONS
37	How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. Schizophrenia Bulletin, 2022, 48, 27-36.	4.3	7
38	Antipsychotic drugs <i>v.</i> barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. Psychological Medicine, 2020, 50, 2622-2633.	4.5	6
39	Decreasing risk of psychosis by sulforaphane study protocol for a randomized, doubleâ€blind, placeboâ€controlled, clinical multiâ€centre trial. Microbial Biotechnology, 2021, 15, 585-594.	1.7	6
40	Choice of maintenance medication for schizophrenia. Journal of Clinical Psychiatry, 2003, 64 Suppl 16, 24-33.	2.2	6
41	Second-generation antipsychotics and quality of life in schizophrenia. Lancet Psychiatry, the, 2016, 3, 694-695.	7.4	4
42	<i>Bacteriology and Comorbidities in Patients Requiring Surgical Management of Empyema</i> American Surgeon, 2018, 84, 599-603.	0.8	4
43	Essential role for neuronal nitric oxide synthase in acute ethanol-induced motor impairment. Nitric Oxide - Biology and Chemistry, 2020, 100-101, 50-56.	2.7	3
44	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophrenia Research, 2021, 230, 87-94.	2.0	2
45	The Incidence of Seizures With Antipsychotics. Journal of Clinical Psychiatry, 2016, 77, e590-e590.	2,2	1